National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) for advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma (1L). HTA ID: 21049.

Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5.

 

NCPE Assessment Process Complete
Rapid review commissioned 01/11/2021
Rapid review completed 29/11/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 07/12/2021
Pre-submission consultation with Applicant Scheduled
Current Status Pre-submission consultation with Applicant scheduled